MCID: HYP082
MIFTS: 43

Hypopharynx Cancer malady

Categories: Rare diseases, Cancer diseases, Gastrointestinal diseases, Oral diseases

Aliases & Classifications for Hypopharynx Cancer

Aliases & Descriptions for Hypopharynx Cancer:

Name: Hypopharynx Cancer 12 14
Hypopharyngeal Cancer 12 50 52 69
Hypopharyngeal Neoplasms 42 69
Malignant Neoplasm of Ill-Defined Sites Within the Lip and Oral Cavity 12
Malignant Neoplasm of Other Specified Sites of Hypopharynx 12
Malignant Neoplasm of Other Specified Hypopharyngeal Site 12
Malignant Neoplasm of Posterior Hypopharyngeal Wall 12
Malignant Neoplasm of Posterior Wall of Hypopharynx 12
Malignant Tumor of Posterior Wall of Hypopharynx 12
Malignant Neoplasm of Hypopharynx, Nos 12
Malignant Neoplasm of Hypopharynx Nos 12
Malignant Neoplasm of Hypopharynx 12
Malignant Tumour of Hypopharynx 12
Malignant Hypopharyngeal Tumor 12
Malignant Tumor of Hypopharynx 12
Hypopharyngeal Carcinoma 69

Classifications:



External Ids:

Disease Ontology 12 DOID:8533
ICD9CM 35 148 148.3 148.9
MeSH 42 D007012
NCIt 47 C7190

Summaries for Hypopharynx Cancer

Disease Ontology : 12 A pharynx cancer that is located in the hypopharynx.

MalaCards based summary : Hypopharynx Cancer, also known as hypopharyngeal cancer, is related to chronic intestinal vascular insufficiency and postcricoid region cancer. An important gene associated with Hypopharynx Cancer is MET (MET Proto-Oncogene, Receptor Tyrosine Kinase), and among its related pathways/superpathways are FGF signaling pathway and Arf6 trafficking events. The drugs Nicotine and Gabapentin have been mentioned in the context of this disorder. Affiliated tissues include the hypopharynx, and related phenotypes are Increased shRNA abundance (Z-score > 2) and neoplasm

Wikipedia : 71 Hypopharyngeal cancer is a disease in which malignant cells grow in the hypopharynx (the area where the... more...

Related Diseases for Hypopharynx Cancer

Graphical network of the top 20 diseases related to Hypopharynx Cancer:



Diseases related to Hypopharynx Cancer

Symptoms & Phenotypes for Hypopharynx Cancer

GenomeRNAi Phenotypes related to Hypopharynx Cancer according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.62 MMP8
2 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.62 MSMO1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.62 MSMO1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.62 MSMO1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.62 GNB1L
6 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.62 MMP8
7 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.62 MSMO1 GNB1L MMP8
8 Increased shRNA abundance (Z-score > 2) GR00366-A-208 9.62 MMP8
9 Increased shRNA abundance (Z-score > 2) GR00366-A-21 9.62 MSMO1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-41 9.62 MMP8
11 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.62 GNB1L
12 Increased shRNA abundance (Z-score > 2) GR00366-A-5 9.62 MMP8
13 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.62 MMP8
14 Increased shRNA abundance (Z-score > 2) GR00366-A-57 9.62 MSMO1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.62 MMP8
16 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.62 GNB1L
17 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.62 GNB1L
18 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.62 MMP8
19 Increased mitotic index GR00110-A-0 9.13 MET NME1 PRKAA2

MGI Mouse Phenotypes related to Hypopharynx Cancer:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.02 CDH1 MET MMP8 NME1 SMUG1

Drugs & Therapeutics for Hypopharynx Cancer

Drugs for Hypopharynx Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 324)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicotine Approved Phase 4 54-11-5 942 89594
2
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
3 Analgesics Phase 4,Phase 3,Phase 1,Phase 2
4 Cholinergic Agents Phase 4,Phase 3,Phase 2
5 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
6 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
7 Psychotropic Drugs Phase 4,Phase 3,Phase 2
8 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
9 Autonomic Agents Phase 4,Phase 3,Phase 2
10 Antiparkinson Agents Phase 4,Phase 3
11 Nicotinic Agonists Phase 4
12 Calcium, Dietary Phase 4,Phase 3,Phase 2
13 Central Nervous System Depressants Phase 4,Phase 3,Phase 2
14 Central Nervous System Stimulants Phase 4,Phase 3
15 calcium channel blockers Phase 4,Phase 2
16 GABA Agents Phase 4
17 Tranquilizing Agents Phase 4,Phase 2
18 Anti-Anxiety Agents Phase 4,Phase 2
19
gamma-Aminobutyric Acid Phase 4 56-12-2 119
20 Excitatory Amino Acid Antagonists Phase 4
21 Excitatory Amino Acids Phase 4
22 Anticonvulsants Phase 4,Phase 2
23 Antimanic Agents Phase 4
24 arginine Nutraceutical Phase 4,Phase 2,Phase 1
25 Omega 3 Fatty Acid Nutraceutical Phase 4,Phase 2
26
Paclitaxel Approved, Vet_approved Phase 3,Phase 1,Phase 2 33069-62-4 36314
27
Cisplatin Approved Phase 3,Phase 2,Phase 1,Early Phase 1 15663-27-1 84093 441203 2767
28
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
29
Epinephrine Approved, Vet_approved Phase 3,Phase 2 51-43-4 5816
30
Hydroxyurea Approved Phase 3,Phase 2,Phase 1 127-07-1 3657
31
Cetuximab Approved Phase 3,Phase 2,Phase 1,Early Phase 1 205923-56-4 56842117 2333
32
Citalopram Approved Phase 3 59729-33-8 2771
33 Tegafur Approved Phase 3,Phase 2 17902-23-7
34
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
35
Epirubicin Approved Phase 3,Phase 2,Phase 1 56420-45-2 41867
36
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
37
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
38
Fluconazole Approved Phase 2, Phase 3 86386-73-4 3365
39
Bleomycin Approved Phase 3 11056-06-7 5360373
40
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
41
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
42
Pilocarpine Approved Phase 2, Phase 3 54-71-7, 92-13-7 5910
43
Isotretinoin Approved Phase 3,Phase 2 4759-48-2 5538 5282379
44
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
45
Megestrol acetate Approved, Vet_approved Phase 3 595-33-5 11683
46
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
47
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
48
Levoleucovorin Approved Phase 3,Phase 2 68538-85-2
49
Succinylcholine Approved Phase 3,Phase 2,Phase 1 306-40-1 5314
50
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774

Interventional clinical trials:

(show top 50) (show all 425)
id Name Status NCT ID Phase
1 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4
2 Comparison of Two Immunomodulatory Formulas on the Number of Postoperative Infections in Head & Neck Cancer Patients Completed NCT02622880 Phase 4
3 Effect of Gabapentin on Postoperative Pain Control Among Head and Neck Cancer Patients Recruiting NCT02926573 Phase 4
4 Parotid-Sparing Intensity-Modulated Radiation Therapy Compared With Conventional Radiation Therapy in Treating Patients With Oropharyngeal or Hypopharyngeal Cancer Who Are at High Risk of Radiation-Induced Xerostomia Unknown status NCT00081029 Phase 3
5 Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Advanced Cancer of the Oropharynx or Hypopharynx Unknown status NCT00003627 Phase 3
6 Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer Unknown status NCT00022373 Phase 3
7 PET/CT Scan-Guided Watchful Waiting or Neck Dissection of Locally Advanced Lymph Node Metastases in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Primary Head And Neck Cancer Unknown status NCT00720070 Phase 3
8 S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck Cancer Unknown status NCT00336947 Phase 3
9 Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer Unknown status NCT00002659 Phase 3
10 Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE) Unknown status NCT00117572 Phase 3
11 Double-blind, Placebo-controlled, Randomized Study of the Effectiveness of Escitalopram on Emotional Distress of Head and Neck Cancer Patients During Cancer Treatment Unknown status NCT00935675 Phase 3
12 Combination Chemotherapy Plus Radiation Therapy To Preserve the Larynx in Patients With Cancer of the Hypopharynx or Larynx Completed NCT00002839 Phase 3
13 Induction CT by Cisplatin, 5FU With or Without Docetaxel in Patients With T3 and T4 Larynx and Hypopharynx Carcinoma Completed NCT00169182 Phase 3
14 Low-level Laser Therapy to Prevent Oral Mucositis in Head and Neck Patients Completed NCT01439724 Phase 3
15 Very Intense Radiotherapy-Chemotherapy Regimen in Advanced HNSCC Completed NCT00162708 Phase 2, Phase 3
16 Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC Completed NCT00158652 Phase 3
17 Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer Completed NCT00008398 Phase 3
18 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
19 Fruit and Vegetable Extracts in Treating Patients With Stage I-IV, Stage IVA/IVB Head and Neck Cancer Completed NCT00064298 Phase 3
20 Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00002533 Phase 2, Phase 3
21 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
22 Oral Mucositis in Patients Receiving Radiation Therapy for Cancer of the Mouth, Pharynx, or Larynx Completed NCT00004234 Phase 3
23 Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer Completed NCT00002507 Phase 3
24 Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00656513 Phase 2, Phase 3
25 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3
26 Radiation Therapy in Treating Patients With Head and Neck Cancer Completed NCT00021125 Phase 3
27 Radiation Therapy With or Without Epoetin Alfa in Treating Anemic Patients With Head and Neck Cancer Completed NCT00004917 Phase 3
28 Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer Completed NCT00006799 Phase 3
29 Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive Tract Completed NCT00765440 Phase 3
30 Combination Chemotherapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00002888 Phase 3
31 Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Completed NCT00003809 Phase 3
32 Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00002476 Phase 3
33 Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer That Has Been Removed During Surgery Completed NCT00002670 Phase 3
34 Fractionated Radiation Therapy in Treating Advanced Squamous Cell Carcinoma of the Head and Neck Completed NCT00771641 Phase 3
35 Radiation Therapy Cisplatin With or Without Fluorouracil Patients With Stage III or Stage IV Head and Neck Cancer Completed NCT00608205 Phase 3
36 Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial) Completed NCT00095875 Phase 3
37 Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer Completed NCT00003592 Phase 3
38 Surgery and Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer That Can Be Removed During Surgery Completed NCT00003576 Phase 3
39 Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Head and Neck Cancer Completed NCT00002654 Phase 3
40 Radiation Therapy Plus Porfiromycin in Treating Patients With Stage III or Stage IV Head and Neck Cancer Completed NCT00003328 Phase 3
41 Biafine Cream to Reduce Side Effects of Radiation Therapy in Patients Receiving Treatment for Advanced Head and Neck Cancer Completed NCT00006481 Phase 3
42 High-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer Completed NCT00002555 Phase 3
43 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00003888 Phase 3
44 Isotretinoin, Interferon Alfa, and Vitamin E in Treating Patients With Stage III or Stage IV Head and Neck Cancer Completed NCT00054561 Phase 3
45 Radiation Therapy in Treating Patients With Metastases to the Lymph Nodes in the Neck From an Unknown Primary Tumor Completed NCT00047125 Phase 3
46 Concomitant Radiation and Cisplatin With and Without Tirapazamine in Treatment of Advanced Head and Neck Cancer Completed NCT00094081 Phase 3
47 Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer Completed NCT00101582 Phase 3
48 Laser Mucite ORL : Effectiveness of Laser Therapy for Mucositis Induced by a Radio-chemotherapy in Head and Neck Cancer Recruiting NCT01772706 Phase 3
49 Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck Recruiting NCT02236936 Phase 3
50 Definitive Chemo-Radiotherapy for Regionally Advanced Head and Neck Cancer With or Without Up-front Neck Dissection Recruiting NCT02918955 Phase 3

Search NIH Clinical Center for Hypopharynx Cancer

Cochrane evidence based reviews: hypopharyngeal neoplasms

Genetic Tests for Hypopharynx Cancer

Anatomical Context for Hypopharynx Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Hypopharynx Cancer:

18
The Hypopharynx

Publications for Hypopharynx Cancer

Articles related to Hypopharynx Cancer:

(show all 20)
id Title Authors Year
1
Sequential four-drug chemotherapy and intensity-modulated radiotherapy for larynx preservation in resectable advanced larynx and hypopharynx cancer: A pilot study. ( 27825651 )
2017
2
Comparative planning of flattening-filter-free and flat beam IMRT for hypopharynx cancer as a function of beam and segment number. ( 24722621 )
2014
3
HPV: a factor in organ preservation for locally advanced larynx and hypopharynx cancer? ( 24119488 )
2014
4
Potential biomarkers for paclitaxel sensitivity in hypopharynx cancer cell. ( 24294361 )
2013
5
Videostroboscopic and morphological aspects of voice disturbances in patients with larynx atrophy and coexisting hypopharynx cancer. ( 22252761 )
2011
6
Radiochemotherapy versus surgery plus radio(chemo)therapy for stage T3/T4 larynx and hypopharynx cancer - results of a matched-pair analysis. ( 21726998 )
2011
7
Impact of combination therapy on disease free survival in hypopharynx cancer. ( 21340251 )
2010
8
Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation. ( 19179556 )
2009
9
The importance of pre-epiglottis space invasion in the treatment planning of larynx and hypopharynx cancer. ( 18392505 )
2008
10
Retropharyngeal nodes in hypopharynx cancer on positron emission tomography. ( 17290070 )
2007
11
Morphological aspect of voice disturbances of aged persons coexisting hypopharynx cancer. ( 17951171 )
2007
12
Prognostic impact of the epidermal growth factor receptor levels for patients with larynx and hypopharynx cancer. ( 15743695 )
2005
13
The influence of RBE variations in a clinical proton treatment plan for a hypopharynx cancer. ( 15930601 )
2005
14
Occupation and larynx and hypopharynx cancer: an international case-control study in France, Italy, Spain, and Switzerland. ( 12814199 )
2003
15
Occupation and larynx and hypopharynx cancer: a job-exposure matrix approach in an international case-control study in France, Italy, Spain and Switzerland. ( 12814200 )
2003
16
Role of multimodal treatment in oropharynx, larynx, and hypopharynx cancer. ( 11291134 )
2001
17
Detection of the proto-oncogene eIF4E in larynx and hypopharynx cancers. ( 10037284 )
1999
18
Larynx preservation with combined chemotherapy and radiation therapy in advanced hypopharynx cancer. ( 8028939 )
1994
19
Endoscopic treatment of supraglottic and hypopharynx cancer. ( 8295459 )
1994
20
SURGICAL TREATMENT OF LARYNX AND HYPOPHARYNX CANCER. ( 14090428 )
1964

Variations for Hypopharynx Cancer

Expression for Hypopharynx Cancer

Search GEO for disease gene expression data for Hypopharynx Cancer.

Pathways for Hypopharynx Cancer

GO Terms for Hypopharynx Cancer

Cellular components related to Hypopharynx Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytoplasmic side of plasma membrane GO:0009898 8.62 CDH1 GNB1L

Biological processes related to Hypopharynx Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cholesterol biosynthetic process GO:0006695 9.16 MSMO1 PRKAA2
2 sterol biosynthetic process GO:0016126 8.96 MSMO1 PRKAA2
3 entry of bacterium into host cell GO:0035635 8.62 CDH1 MET

Sources for Hypopharynx Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....